Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.20%
1,108.23
-2.24
-0.20%
—1,110.471,107.751,111.341,093.81——
SIXC
Communications
SIXC
Communications
SIXC
+0.26%
605.63
+1.56
+0.26%
—604.07604.07606.04600.91——
SIXE
Energy
SIXE
Energy
SIXE
+0.70%
1,209.95
+8.46
+0.70%
—1,201.491,205.921,215.311,201.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.40%
1,758.23
-7.07
-0.40%
—1,765.301,764.031,764.031,736.40——
SIXM
Financials
SIXM
Financials
SIXM
+0.72%
634.94
+4.52
+0.72%
—630.42630.34636.69626.03——
SIXR
Staples
SIXR
Staples
SIXR
+1.30%
852.37
+10.92
+1.30%
—841.45843.60858.11840.11——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.01%
218.85
+0.020
+0.01%
—218.83218.83219.32217.33——
SIXT
Technology
SIXT
Technology
SIXT
-1.50%
3,528.49
-53.74
-1.50%
—3,582.233,550.603,562.623,447.78——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.10%
914.82
+0.93
+0.10%
—913.89912.75918.12906.67——
SIXV
Health care
SIXV
Health care
SIXV
+1.93%
1,472.27
+27.94
+1.93%
—1,444.331,446.871,480.741,446.30——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.93%
2,390.61
-22.35
-0.93%
—2,412.962,403.992,411.412,373.90——
NBIX:NASDAQ
Neurocrine Biosciences Inc
$155.80
+3.46%
(+5.21) 1D
$155.80
0.00% (0.00)
After hours
Closed: May 12, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBIX...
Open
$151.43
High
$156.32
Low
$150.82
Mkt. cap
15.67B
Avg. vol.
1.23M
Volume
1.31M
P/E ratio
23.97
52-wk high
$160.18
52-wk low
$116.00
EPS
$6.50
Beta
0.34
Shares outstanding
100.55M
No. of employees
2K
News stories
From sources across the web
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Inc
CEOKevin C. Gorman
Employees2K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
Last report
May 5, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
$1.94 / $1.71
+13.42%beat
Revenue / Est. (USD)
814.50M / 763.79M
+6.64%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
687.50M
794.90M
805.50M
814.50M
Cost of goods sold
255.60M
264.00M
275.80M
310.00M
Cost of revenue
255.60M
264.00M
275.80M
310.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
286.30M
291.60M
302.50M
318.50M
Operating expense
286.30M
291.60M
302.50M
318.50M
Total operating expenses
541.90M
555.60M
578.30M
628.50M
Operating income
145.60M
239.30M
227.20M
186.00M
Other non operating income
-
-
-
-
EBT including unusual items
159.50M
291.80M
239.40M
246.80M
EBT excluding unusual items
166.20M
261.50M
253.00M
214.10M
Income tax expense
52.00M
82.30M
85.70M
48.90M
Effective tax rate
32.60%
28.20%
35.80%
19.81%
Other operating expenses
-
-
-
-
Net income
107.50M
209.50M
153.70M
197.90M
Net profit margin
15.64%
26.36%
19.08%
24.30%
Earnings per share
1.65
2.17
1.88
1.94
Interest and investment income
20.60M
22.20M
25.80M
28.10M
Interest expense
-
-
-
-
Net interest expenses
20.60M
22.20M
25.80M
28.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
152.90M
247.00M
234.70M
193.30M
Gain or loss from assets sale
-
-
-
-28.60M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer